Tumor regression by means of magnetic drug targeting. (December 2009)

• Record Type: Journal Article
• Authors: Krukemeyer, MG; Wagner, W; Jakobs, M; Krenn, V
• Is Part Of: Nanomedicine. Volume 4:Number 8(2009)
• Page Start: 875
• Page End: 882
• Publication Date: 2009-12
• Subjects: iron oxide -- magnetic drug targeting -- magnetic field -- tumor; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm.09.73
• Languages: English
• ISSNs: 1743-5889

Abstract

The expression ''magnetic drug targeting'' is understood as meaning the targeted administration of a drug, for example, a cytostatic, with the intention of optimizing the local therapeutic effect. A magnetic field strength of 0.6 T is applied externally to the body. Iron oxides are administered intravasally into a vein. Cytostatics are bonded to the iron oxides. This form of administration, also known as sluicing, is particularly suitable for cytostatics, since the intention is to achieve a high concentration of the cytostatic at the target site (site of the tumor), but to minimize the harmful effect in the rest of the tissue. A reduction in tumor volume under the magnetic field and in the liver of 45––90% has been detected by MRI.